Advertisement
News
Subscribe to MDT Magazine News

SuperNova Diagnostics® to Present at Biotech Showcase™ 2011 During J.P. Morgan Healthcare Conference January 10-13

January 5, 2011 5:34 am | by Bio-Medicine.Org | Comments

WASHINGTON, LONDON and HONG KONG, Jan. 5, 2011 /- SuperNova Diagnostics®, Inc., a privately-held global diagnostics company for human and non-human health applications, announced today that Neil J. Campbell, president and CEO, will present at Biotech Showcase 2011 in conjunction with...

TOPICS:

Helena Laboratories to Manage BIS and OFAC Screening via ATTUS WatchDOG® Pro

January 5, 2011 5:34 am | by Bio-Medicine.Org | Comments

CHARLOTTE, N.C., Jan. 5, 2011 /- ATTUS Technologies, Inc , adds Helena Laboratories, a clinical laboratory instrument and reagent manufacturer, to the growing list of global companies choosing the market leading WatchDOG® Pro for their BIS, OFAC and other watch list screening...

TOPICS:

Elekta's MOSAIQ Oncology Information System Named Category Leader in '2010 Top 20 Best in KLAS Awards' Report

January 5, 2011 5:34 am | by Bio-Medicine.Org | Comments

ATLANTA, Jan. 5, 2011 /- Elekta's MOSAIQ® Oncology Information System (OIS)—the market's leading open-system, vendor-neutral OIS—has earned the No. 1 ranking in the oncology software category from KLAS, an independent research firm. According to KLAS, a Category Leader...

TOPICS:
Advertisement

Estrogen May Help Precancerous Cells Spread in Oral Cavity

January 5, 2011 5:33 am | by AACR | Comments

PHILADELPHIA - Head and neck cancer is the sixth most common type of cancer and is on the rise in some demographic groups, including young women without any known risk factors. Now, researchers at Fox Chase Cancer Center report that estrogen may increase the movement of precancerous cells...

TOPICS:

Federal Register: Draft Guidance for Industry and FDA; Establishing the Performance Characteristics of Nucleic Acid-Based In Vitro Diagnostic Devices for the Detection and Dif...

January 5, 2011 5:30 am | by U.S. Food & Drug Administration | Comments

The draft guidance document provides industry and Agency staff with updated recommendations for studies to establish the analytical and clinical performance of nucleic acid-based in vitro diagnostic devices (IVDs) intended for the detection and...

TOPICS:

Labtiva lands $2M for research software

January 5, 2011 4:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Software developer Labtiva Inc., a company at startup incubator Dogpatch Labs in Cambridge, has secured $2 million in equity financing, according to a regulatory filing. The company is developing research management tools for the life sciences and academic literature industries.

Hamilton CapTel® and Partner TV Ears to Display Telephone Communication Technology Designed for Individuals with Hearing Loss at Consumer Electronics Show

January 5, 2011 3:35 am | by Bio-Medicine.Org | Comments

AURORA, Neb., Jan. 5, 2011 /- Consumer Electronics Show Las Vegas Convention Center Booth #2910. For the first time, Hamilton CapTel ® will demonstrate the CapTel 800i® captioned telephone for more than 100,000 attendees at the Consumer Electronics Show (CES) in Las Vegas...

TOPICS:

Water Street Healthcare Partners Acquires OraPharma, Inc.

January 5, 2011 3:34 am | by Bio-Medicine.Org | Comments

CHICAGO, Jan. 5, 2011 /- Water Street Healthcare Partners announced today that it has acquired OraPharma, Inc. from Johnson & Johnson.  Water Street, a strategic private equity firm focused exclusively on health care, plans to build OraPharma into a leading specialty...

TOPICS:
Advertisement

DJO Incorporated Acquires Manufacturer of Compression Therapy Products, Elastic Therapy, Inc.

January 5, 2011 3:34 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Jan. 5, 2011 /- DJO Incorporated ("DJO" or the "Company"), a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced the acquisition of Elastic Therapy, Inc. (ETI). The acquisition closed yesterday, January 4,...

TOPICS:

New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion

January 5, 2011 3:33 am | by Bio-Medicine.Org | Comments

RIDGEFIELD, Conn., Jan. 5, 2011 /- Results of a post-hoc analysis of the RE-LY® trial among patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion, a treatment to convert an abnormal heartbeat back to normal sinus rhythm, were published online on Jan. 3 in...

TOPICS:

InterMune to Present at J.P. Morgan Healthcare Conference

January 5, 2011 3:33 am | by Bio-Medicine.Org | Comments

BRISBANE, Calif., Jan. 5, 2011 /- InterMune, Inc. (Nasdaq: ITMN ) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12, 2011, at 4:30 p.m. EST / 1:30...

TOPICS:

Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued

January 5, 2011 2:35 am | by Bio-Medicine.Org | Comments

PALO ALTO, Calif., Jan. 5, 2011 /- Carbylan BioSurgery, Inc. announced today the completion of patient enrollment in their double-blinded, multi-center COR1.0 feasibility trial to evaluate the safety and effectiveness of two products - Hydros and Hydros TA Joint Therapies - in patients...

TOPICS:

Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 12

January 5, 2011 2:35 am | by Bio-Medicine.Org | Comments

PALO ALTO, Calif., Jan. 5, 2011 /- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today that the company will make a presentation at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 12, 2011 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time.  Bruce...

TOPICS:

ImmunGene Announces Multi-Target R & D Collaboration With Cephalon Australia for Interferon Payload Technology

January 5, 2011 12:35 am | by Bio-Medicine.Org | Comments

THOUSAND OAKS, Calif., Jan. 5, 2011 /- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's...

TOPICS:

Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 Injection

January 4, 2011 10:34 pm | by Bio-Medicine.Org | Comments

NEW YORK, Jan. 5, 2011 /PRNewswire-Asia/ -- Dongsheng Pharmaceutical International Co., Ltd. (the "Company") (OTC Bulletin Board: DNGH ) announced today that it has obtained the exclusive sales rights of Thymosin Alpha 1 Injection in 19 provinces in China from Shanghai Biochemistry...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading